Literature DB >> 1795632

Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization.

N Guiso1, M Szatanik, M Rocancourt.   

Abstract

Bordetella pertussis synthesizes several factors. It has been suggested that one of these factors, the adenylate cyclase-hemolysin (AC-Hly), directly penetrates target cells and impairs their normal functions by elevating intracellular cAMP. In the present study, we show that active immunization with purified B. pertussis AC-Hly or AC (a fragment of the AC-Hly molecule carrying only the adenylate cyclase activity but no toxin activity in vitro) protects mice against B. pertussis intranasal infection. Immunization with AC-Hly or AC significantly shortens the period of bacterial colonization of the mouse respiratory tract. Furthermore, B. parapertussis AC-Hly or AC are also protective antigens against B. parapertussis colonization; their protective activities are equivalent to that of the whole-cell vaccine. These results suggest that AC-Hly may play an important role in Bordetella pathogenesis, in a murine model. If this factor plays a similar role in the human disease, its use as a protective antigen could reduce not only the incidence of the disease, but also the asymptomatic human reservoir by limiting bacterial carriage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795632     DOI: 10.1016/0882-4010(91)90038-c

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  23 in total

1.  Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin.

Authors:  S J Lee; M C Gray; L Guo; P Sebo; E L Hewlett
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Bordetella bronchiseptica persists in the nasal cavities of mice and triggers early delivery of dendritic cells in the lymph nodes draining the lower and upper respiratory tract.

Authors:  Pascale Gueirard; Patrick Ave; Anne-Marie Balazuc; Sabine Thiberge; Michel Huerre; Genevieve Milon; Nicole Guiso
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.

Authors:  E Grimprel; P Bégué; I Anjak; E Njamkepo; P François; N Guiso
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 4.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 5.  Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools.

Authors:  Nicholas H Carbonetti
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

6.  Isolation of Bordetella bronchiseptica from a patient with AIDS.

Authors:  R Mesnard; N Guiso; C Michelet; J M Sire; P Pouëdras; P Y Donnio; J L Avril
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

7.  The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin.

Authors:  F Betsou; P Sebo; N Guiso
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Virulence of Bordetella bronchiseptica: role of adenylate cyclase-hemolysin.

Authors:  P Gueirard; N Guiso
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Western blot analysis of antibody responses of young infants to pertussis infection.

Authors:  N Guiso; E Grimprel; I Anjak; P Bégué
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

10.  CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin.

Authors:  F Betsou; P Sebo; N Guiso
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.